Liquid cultures

The CPTR Biomarkers & Clinical Endpoints Workgroup (BCE-WG) has evaluated relevant research on liquid media culture as a TB drug development tool, which provides the benefit of measurements at various time points during clinical trials of TB therapeutics as an early prognostic/predictive biomarker for non-relapsing cure. The BCE-WG is pursuing regulatory endorsement of this tool by regulatory agencies. The Liquid Culture sub team submitted an official meeting request for a Type B meeting with FDA via the pre-IND process, scheduled for June 2014. This sub team is also pursuing EMA review and endorsement.